Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Repeat VTE risk heightened in HIV patients

Key clinical point: VTE risk factors look unique to HIV.

Major finding: HIV-positive patients were at a 67% increased risk of repeat VTE in the first year after stopping anticoagulant therapy.

Study details: Retrospective analysis of repeat VTE (n = 4,158). Retrospective analysis of first-time VTE (n = 357).

Disclosures: The first-time VTE study was funded by the National Institutes of Health. The repeat VTE study was funded by the Dutch government. Dr. Crane and Dr. Reiss have no conflicts of interest.


Rokx C et al. CROI 2019, Abstract 636; and Tenforde MW et al. CROI 2019, Abstract 637.